Contact this trialFirst, we need to learn more about you.
Janus Kinase (JAK) Inhibitor
Ruxolitinib for Precancerous Breast Conditions
Recruiting0 awardsPhase 2
Indianapolis, Indiana
This trial is testing if the drug ruxolitinib can kill premalignant breast cells. Half the participants will get the drug and half will get a placebo for 15 days, then all will have surgery to remove the cells.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.